Home
>
National Drug Code (NDC)
>
LAMIVUDINE AND ZIDOVUDINE
LAMIVUDINE AND ZIDOVUDINE - 68180-284-07 - (LAMIVUDINE AND ZIDOVUDINE)
Drug Information of LAMIVUDINE AND ZIDOVUDINE
| Product NDC: | 68180-284 |
| Proprietary Name: | LAMIVUDINE AND ZIDOVUDINE |
| Non Proprietary Name: | LAMIVUDINE AND ZIDOVUDINE |
| Active Ingredient(s): | 150; 300 mg/1; mg/1 & nbsp; LAMIVUDINE AND ZIDOVUDINE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of LAMIVUDINE AND ZIDOVUDINE
| Product NDC: | 68180-284 |
| Labeler Name: | Lupin Pharmaceuticals, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA090246 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120514 |
Package Information of LAMIVUDINE AND ZIDOVUDINE
| Package NDC: | 68180-284-07 |
| Package Description: | 60 TABLET in 1 BOTTLE (68180-284-07) |
NDC Information of LAMIVUDINE AND ZIDOVUDINE
| NDC Code | 68180-284-07 |
| Proprietary Name | LAMIVUDINE AND ZIDOVUDINE |
| Package Description | 60 TABLET in 1 BOTTLE (68180-284-07) |
| Product NDC | 68180-284 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | LAMIVUDINE AND ZIDOVUDINE |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20120514 |
| Marketing Category Name | ANDA |
| Labeler Name | Lupin Pharmaceuticals, Inc. |
| Substance Name | LAMIVUDINE; ZIDOVUDINE |
| Strength Number | 150; 300 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
